Use of an H+, K+ -ATPase inhibitor in the treatment of asthma

Abstract

The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H + , K + -ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.

1 - 11 . (canceled)  
   
   
       12 . A method for the treatment of asthma which comprises simultaneously, separately or sequentially administration to a subject suffering from asthma with a pharmaceutical formulation comprising an H + , K + -ATPase inhibitor and a glucocorticoid, wherein the H + , K + -ATPase inhibitor is a compound of the formula  
     
       
         
         
             
             
         
       
     
     wherein Het 1  is  
     
       
         
         
             
             
         
       
     
     Het 2  is  
     
       
         
         
             
             
         
       
     
     and X is  
     
       
         
         
             
             
         
       
     
     wherein N in the benzimidazole moiety of Het 2  means that one of the ring carbon atoms substituted by R 6  R 9  optionally ma be exchanged for a nitrogen atom without any substituents; 
 R 1  and R 3  each independently represent hydrogen, alkyl, or on the condition that R 1  and R 3  do not simultaneously represent alkoxy; and R 2  represents alkyl, alkoxy optionally substituted by fluorine, alkylthio or alkoxyalkoxy; or one of R 1  and R 3  is halogen and the other is hydrogen and R 2  is 1-morpholino, 1-piperidino or dialkylamino;  
 R 4  and R 5  are the same or different and selected from hydrogen and alkyl;  
 R 6 -R 9  are the same or different and selected from hydrogen, halogen, alkyl, alkoxy, haloalkoxy, alkylcarbonyl, and alkoxycarbonyl;  
 R 10  is hydrogen or R 10  and R 3  together complete a ring containing 6 to 8 carbon atoms; and  
 R 11  represents hydrogen, halogen or alkyl;  
 wherein each alkyl or alkoxy moiety in the preceding substituents has a branched or straight chain and has 1 to 6 carbon atoms.  
 
   
   
       13 . The method according to  claim 12 , wherein the glucocorticoid is a topically active anti-inflammatory steroid.  
   
   
       14 - 18 . (canceled)  
   
   
       19 . The method according to  claim 13 , wherein the glucocorticoid is budesonide, beclomethasone dipropionate or fluticasone propionate.  
   
   
       20 . The method according to claim  14 , wherein the compound of formula (I) is in the form of a pharmaceutically acceptable alkaline salt or in its neutral form or is a single enantiomer or a racemate thereof.  
   
   
       21 . The method according to claim  14 , wherein the compound of formula (I) is a compound of formula  
     
       
         
         
             
             
         
       
     
   
   
       22 . The method according to  claim 21 , wherein the compound of formula (Ia) is in the neutral form or in the form of a pharmaceutically acceptable salt, a single enantiomer or a racemate o the compound.  
   
   
       23 . The method according to anyone of claims  12 ,  13  or  19 - 22 , wherein the compound is omeprazole, the (−)-enantiomer of omeprazole, an alkaline salt of omeprazole or an alkaline salt of the (−)-enantiomer of omeprazole.